Gregory M Vercellotti

List of Publications by Year
in descending order

180	8,534	71102 41	46799 89
papers	citations	h-index	g-index

181	181	181	8577
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A case of VEXAS syndrome associated with EBV-associated hemophagocytic lymphohistiocytosis. Blood Cells, Molecules, and Diseases, 2022, 93, 102636.	1.4	14
2	Plasma-Derived Hemopexin as a Candidate Therapeutic Agent for Acute Vaso-Occlusion in Sickle Cell Disease: Preclinical Evidence. Journal of Clinical Medicine, 2022, 11, 630.	2.4	15
3	Phase 2 Results of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor As Treatment for Life-Threatening Acute Gvhd. Transplantation and Cellular Therapy, 2022, 28, S58-S59.	1.2	0
4	Evidence for complement-mediated bone marrow necrosis in a young adult with sickle cell disease. Blood Cells, Molecules, and Diseases, 2021, 86, 102508.	1.4	3
5	Noncanonical Roles of Caspase-4 and Caspase-5 in Heme-Driven IL-1Î² Release and Cell Death. Journal of Immunology, 2021, 206, 1878-1889.	0.8	19
6	Soluble MD-2 and Heme in Sickle Cell Disease Plasma Promote Pro-Inflammatory Signaling in Endothelial Cells. Frontiers in Immunology, 2021, 12, 632709.	4.8	8
7	Vasculoâ€toxic and proâ€inflammatory action of unbound haemoglobin, haem and iron in transfusionâ€dependent patients with haemolytic anaemias. British Journal of Haematology, 2021, 193, 637-658.	2.5	22
8	High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group. Blood Cancer Journal, 2021, 11, 96.	6.2	4
9	Multiple inducers of endothelial <scp>NOS</scp> (<scp>eNOS</scp>) dysfunction in sickle cell disease. American Journal of Hematology, 2021, 96, 1505-1517.	4.1	7
10	Low Incidence of Chronic Graft-Versus-Host Disease in Myeloablative Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Using Matched Related or Unrelated Donors: Phase II Study Interim Analysis. Blood, 2021, 138, 1811-1811.	1.4	0
11	Synthetic Heparan Sulfate Compounds Attenuate Vascular Complications Associated with Sickle Cell Disease. Blood, 2021, 138, 857-857.	1.4	0
12	ML-0207/ASP8731: A Novel BACH1 Inhibitor That Induces Fetal Hemoglobin in Treatment of Sickle Cell Disease. Blood, 2021, 138, 854-854.	1.4	3
13	Updated Results of a Phase 1/2 Clinical Study of Zinc Finger Nuclease-Mediated Editing of BCL11A in Autologous Hematopoietic Stem Cells for Transfusion-Dependent Beta Thalassemia. Blood, 2021, 138, 3974-3974.	1.4	10
14	Phase 2 Results of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor As Treatment for Life-Threatening Acute Gvhd. Blood, 2021, 138, 261-261.	1.4	4
15	A Vanishing Cecal Mass: A Rare Gastrointestinal Manifestation of Systemic Mastocytosis. Cureus, 2021, 13, e20784.	0.5	0
16	A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease. Haematologica, 2020, 105, 623-631.	3.5	39
17	Decreased erythrocyte binding of Siglec-9 increases neutrophil activation in sickle cell disease. Blood Cells, Molecules, and Diseases, 2020, 81, 102399.	1.4	11
18	Thrombin activation of PAR-1 contributes to microvascular stasis in mouse models of sickle cell disease. Blood, 2020, 135, 1783-1787.	1.4	32

#	Article	IF	Citations
19	Renal Functional Decline in Sickle Cell Disease and Trait. Journal of the American Society of Nephrology: JASN, 2020, 31, 236-238.	6.1	4
20	Itâ€™s all in the film. British Journal of Haematology, 2020, 189, 8-8.	2.5	0
21	Identification of a Heme Activation Site on the MD-2/TLR4 Complex. Frontiers in Immunology, 2020, 11, 1370.	4.8	26
22	Antithrombotic effects of heme-degrading and heme-binding proteins. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 318, H671-H681.	3.2	14
23	Case report of an unusual presentation of Staphylococcus aureus induced toxic shock syndrome/hyperimmunoglobulinemia E syndrome. Medicine (United States), 2020, 99, e19746.	1.0	2
24	Facilitating resolution of life-threatening acute GVHD with human chorionic gonadotropin and epidermal growth factor. Blood Advances, 2020, 4, 1284-1295.	5.2	21
25	Endothelial TLR4 Expression Mediates Vaso-Occlusive Crisis in Sickle Cell Disease. Frontiers in Immunology, 2020, 11, 613278.	4.8	20
26	The multifaceted role of ischemia/reperfusion in sickle cell anemia. Journal of Clinical Investigation, 2020, 130, 1062-1072.	8.2	48
27	Ruxolitinib Reduces Endothelial Pro-Adhesive Interactions: Implications for JAK2V617+ MPN Thrombosis. Blood, 2020, 136, 1-1.	1.4	3
28	SARS-CoV-2 severity in African Americans â€“ A role for Duffy Null?. Haematologica, 2020, 105, 2892.	3.5	7
29	Microvascular Stasis Inhibition By Hemopexin in the Townes Mouse Model of Sickle Cell Disease. Blood, 2020, 136, 9-9.	1.4	0
30	Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up. Biology of Blood and Marrow Transplantation, 2019, 25, 56-62.	2.0	9
31	Heme oxygenase-2 protects against ischemic acute kidney injury: influence of age and sex. American Journal of Physiology - Renal Physiology, 2019, 317, F695-F704.	2.7	9
32	Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (PregnylÂ®): A Phase I Study. Biology of Blood and Marrow Transplantation, 2019, 25, S240-S241.	2.0	1
33	A Simpler Answer â€“ After All This Time. American Journal of Medicine, 2019, 132, e37-e38.	1.5	0
34	Reversal of acquired von Willebrand syndrome with allogeneic stem cell transplant for chronic lymphocytic leukemia. Blood Cells, Molecules, and Diseases, 2019, 77, 109-112.	1.4	2
35	First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. Blood Advances, 2019, 3, 1970-1980.	5.2	164
36	Critical role of C5a in sickle cell disease. American Journal of Hematology, 2019, 94, 327-337.	4.1	48

#	Article	IF	Citations
37	Therapeutic strategies for sickle cell disease: towards a multi-agent approach. Nature Reviews Drug Discovery, 2019, 18, 139-158.	46.4	116
38	Intravenous immunoglobulin for treatment of necrobiotic xanthogranuloma. Dermatologic Therapy, 2019, 32, e12744.	1.7	4
39	Preliminary Results of a Phase 1/2 Clinical Study of Zinc Finger Nuclease-Mediated Editing of BCL11A in Autologous Hematopoietic Stem Cells for Transfusion-Dependent Beta Thalassemia. Blood, 2019, 134, 3544-3544.	1.4	29
40	Deletion of TLR4 in Townes SS Mice Prevents Microvascular Stasis in Response to Hemin, LPS and Hypoxia/Reoxygenation: Role of Inflammation. Blood, 2019, 134, 3555-3555.	1.4	1
41	Increased Release of Soluble MD-2 in Sickle Cell Disease and Its Role in Pro-Inflammatory Signaling in Endothelial Cells. Blood, 2019, 134, 208-208.	1.4	0
42	Association between Sensorineural Hearing Loss and Homozygous Sickle Cell Anemia: A Meta-Analysis. Blood, 2019, 134, 3453-3453.	1.4	3
43	Identification of a Heme Activation Site on the MD-2/TLR4 Complex. Blood, 2019, 134, 209-209.	1.4	0
44	Bivalent ligand MCC22 potently attenuates nociception in a murine model of sickle cell disease. Pain, 2018, 159, 1382-1391.	4.2	9
45	Romidepsin-associated cardiac toxicity and ECG changes: A case report and review of the literature. Journal of Oncology Pharmacy Practice, 2018, 24, 56-62.	0.9	17
46	Case series supporting heme detoxification via therapeutic plasma exchange in acute multiorgan failure syndrome resistant to red blood cell exchange in sickle cell disease. Transfusion, 2018, 58, 470-479.	1.6	18
47	Oral carbon monoxide therapy in murine sickle cell disease: Beneficial effects on vaso-occlusion, inflammation and anemia. PLoS ONE, 2018, 13, e0205194.	2.5	37
48	Catheter-Related Thrombosis in Patients with Lymphoma or Myeloma Undergoing Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, e20-e25.	2.0	9
49	Haptoglobin and hemopexin inhibit vaso-occlusion and inflammation in murine sickle cell disease: Role of heme oxygenase-1 induction. PLoS ONE, 2018, 13, e0196455.	2.5	88
50	Serum haptoglobin and hemopexin levels are depleted in pediatric sickle cell disease patients. Blood Cells, Molecules, and Diseases, 2018, 72, 34-36.	1.4	31
51	Catheter-Related Thrombosis in Recipients of Autologous Hematopoietic Cell Transplantation (AHCT) with Myeloma and Lymphoma: Risk Factors and Management. Biology of Blood and Marrow Transplantation, 2018, 24, S135-S136.	2.0	0
52	Role of TLR4 signaling in the nephrotoxicity of heme and heme proteins. American Journal of Physiology - Renal Physiology, 2018, 314, F906-F914.	2.7	31
53	Hemoglobin oxidationâ€“dependent reactions promote interactions with band 3 and oxidative changes in sickle cellâ€“derived microparticles. JCI Insight, 2018, 3, .	5.0	48
54	Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A Phase I Study. Blood, 2018, 132, 71-71.	1.4	2

#	Article	IF	Citations
55	Decreased Erythrocyte Binding Capability for Neutrophil Siglec-9 Is a Source of Oxidative Stress in Sickle Cell Disease. Blood, 2018, 132, 3650-3650.	1.4	0
56	Thrombin-Mediated Activation of PAR-1 Contributes to Microvascular Stasis in Mouse Models of Sickle Cell Disease Via Increased Endothelial Expression of P-Selectin and VWF. Blood, 2018, 132, 266-266.	1.4	0
57	Control of Oxidative Stress and Inflammation in Sickle Cell Disease with the Nrf2 Activator Dimethyl Fumarate. Antioxidants and Redox Signaling, 2017, 26, 748-762.	5.4	95
58	The role of carbon monoxide and heme oxygenase in the prevention of sickle cell disease vasoâ€occlusive crises. American Journal of Hematology, 2017, 92, 569-582.	4.1	33
59	Elevated systemic heme and iron levels as risk factor for vascular dysfunction and atherosclerosis: Evidence from a beta-thalassemia cohort study. Atherosclerosis, 2017, 263, e107-e108.	0.8	3
60	A monocyteâ€TNFâ€endothelial activation axis in sickle transgenic mice: Therapeutic benefit from TNF blockade. American Journal of Hematology, 2017, 92, 1119-1130.	4.1	23
61	<scp>S</scp>trongyloides hyperinfection following hematopoietic stem cell transplant in a patient with <scp>HTLV</scp>â€1â€associated Tâ€cell leukemia. Transplant Infectious Disease, 2017, 19, e12638.	1.7	10
62	Hepatic Overexpression of Hemopexin Inhibits Inflammation and Vascular Stasis in Murine Models of Sickle Cell Disease. Molecular Medicine, 2016, 22, 437-451.	4.4	45
63	Clonal Lymphoproliferations in a Patient With Common Variable Immunodeficiency. Laboratory Medicine, 2016, 47, 318-325.	1.2	3
64	Sustained treatment of sickle cell mice with haptoglobin increases <scp>HO</scp>â€1 and Hâ€ferritin expression and decreases iron deposition in the kidney without improvement in kidney function. British Journal of Haematology, 2016, 175, 714-723.	2.5	16
65	The endothelial protein C receptor rs867186-GG genotype is associated with increased soluble EPCR and could mediate protection against severe malaria. Scientific Reports, 2016, 6, 27084.	3.3	12
66	Complement Activation in a Murine Model of Sickle Cell Disease: Inhibition of Vaso-Occlusion By Blocking C5 Activation. Blood, 2016, 128, 158-158.	1.4	6
67	Haptoglobin and Hemopexin Infusion Efficiently Activates the Nrf2/HO-1 Axis and Inhibits Inflammation and Vaso-Occlusion in Murine Sickle Cell Disease. Blood, 2016, 128, 2477-2477.	1.4	4
68	A Novel, Highly Potent and Selective PDE9 Inhibitor for the Treatment of Sickle Cell Disease. Blood, 2016, 128, 268-268.	1.4	11
69	Serum Haptoglobin and Hemopexin Levels in Pediatric SS and SC Disease Patients: Biomarker of Hemolysis and Inflammation. Blood, 2016, 128, 3649-3649.	1.4	8
70	Hemoglobin S Oxidation Promotes Plasma-Derived Microparticle Membrane Alterations and Toxicity. Blood, 2016, 128, 856-856.	1.4	3
71	Systemic Heme and Iron Overload Results in Depletion of Serum Hemopexin, Haptoglobin and Transferrin and Correlates with Markers of Endothelial Activation and Lipid Oxidation in Beta Thalassemia Major and Intermedia. Blood, 2016, 128, 2469-2469.	1.4	2
72	Reply to Eisenhut. Clinical Infectious Diseases, 2015, 60, 1138-9.	5.8	1

#	Article	IF	Citations
73	Special delivery: microparticles convey heme. Blood, 2015, 125, 3677-3678.	1.4	6
74	ILâ€4 and ILâ€13 induce protection from complement and melittin in endothelial cells despite initial loss of cytoplasmic proteins: membrane resealing impairs quantifying cytotoxicity with the lactate dehydrogenase permeability assay. Xenotransplantation, 2015, 22, 295-301.	2.8	9
75	The Fucosylation Inhibitor, 2-Fluorofucose, Inhibits Vaso-Occlusion, Leukocyte-Endothelium Interactions and NF-Ä¸B Activation in Transgenic Sickle Mice. PLoS ONE, 2015, 10, e0117772.	2.5	27
76	Haptoglobin attenuates hemoglobin-induced heme oxygenase-1 in renal proximal tubule cells and kidneys of a mouse model of sickle cell disease. Blood Cells, Molecules, and Diseases, 2015, 54, 302-306.	1.4	40
77	Circulating Angiogenic Factors Associated with Response and Survival in Patients with Acute Graft-versus-Host Disease: Results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802. Biology of Blood and Marrow Transplantation, 2015, 21, 1029-1036.	2.0	53
78	High Plasma Erythropoietin Levels are Associated With Prolonged Coma Duration and Increased Mortality in Children With Cerebral Malaria. Clinical Infectious Diseases, 2015, 60, 27-35.	5.8	16
79	Hemopexin Gene Therapy Inhibits Inflammation and Vaso-Occlusion in Transgenic Sickle Cell Mice. Blood, 2015, 126, 412-412.	1.4	0
80	Targeting Putative Mu Opioid/Chemokine Receptor Type 5 Heteromers Potently Attenuates Nociception in a Murine Model of Sickle Cell Disease. Blood, 2015, 126, 277-277.	1.4	1
81	Three Months of Human Haptoglobin Treatment Decreases Iron Deposition in the Kidneys of Townes Sickle Mice. Blood, 2015, 126, 2163-2163.	1.4	1
82	H-ferritin ferroxidase induces cytoprotective pathways and inhibits microvascular stasis in transgenic sickle mice. Frontiers in Pharmacology, 2014, 5, 79.	3.5	32
83	De novo CD5â€positive primary cardiac diffuse large Bâ€cell lymphoma diagnosed by pleural fluid cytology. Diagnostic Cytopathology, 2014, 42, 259-267.	1.0	5
84	Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis. Journal of Clinical Oncology, 2014, 32, 3264-3274.	1.6	146
85	Interleukin-4 Induces Up-regulation of Endothelial Cell Claudin-5 through Activation of FoxO1. Journal of Biological Chemistry, 2014, 289, 838-847.	3.4	21
86	Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood, 2014, 123, 377-390.	1.4	555
87	Not simply misshapen red cells: multimolecular and cellular events in sickle vaso-occlusion. Journal of Clinical Investigation, 2014, 124, 1462-1465.	8.2	19
88	Dimethyl Fumarate Induces Cytoprotection and Inhibits Inflammation and Vaso-Occlusion in Transgenic Sickle Mice. Blood, 2014, 124, 219-219.	1.4	2
89	Phenotypic Characterization the Townes Sickle Mice. Blood, 2014, 124, 4916-4916.	1.4	19
90	Carbon Monoxide Expedites Metabolic Exhaustion to Inhibit Tumor Growth. Cancer Research, 2013, 73, 7009-7021.	0.9	295

#	Article	IF	Citations
91	Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood, 2013, 121, 1276-1284.	1.4	582
92	Î²-Globin Sleeping Beauty Transposon Reduces Red Blood Cell Sickling in a Patient-Derived CD34+-Based In Vitro Model. PLoS ONE, 2013, 8, e80403.	2.5	13
93	Vasculotoxic and Proinflammatory Effects of Plasma Heme: Cell Signaling and Cytoprotective Responses. ISRN Oxidative Medicine, 2013, 2013, 1-9.	0.8	46
94	Heme Potently Stimulates Tissue Factor Expression By Peripheral Blood Monocytes: A Novel Mechanism For Thrombosis In Intravascular Hemolytic Diseases. Blood, 2013, 122, 2215-2215.	1.4	8
95	Thiocyanate Blocks Peroxidase-Dependent Extracellular Trap (ET) Formation By PMN and Eosinophils: Heme Is a Potent New Agonist For The ET Pathway. Blood, 2013, 122, 323-323.	1.4	2
96	Interference With TNFÎ± Using Long-Term Etanercept In S+SAntilles Sickle Transgenic Mice Ameliorates Abnormal Endothelial Activation, Vasoocclusion, and Pulmonary Hypertension Including Its Pulmonary Arterial Wall Remodeling. Blood, 2013, 122, 728-728.	1.4	6
97	Bortezomib Is Highly Effective For Pure Red Cell Aplasia After ABO-Incompatible Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 5495-5495.	1.4	0
98	Allogeneic Hematopoietic Cell Transplantation Is Effective In Patients With Advanced Systemic Mastocytosis: A Multicenter Retrospective Analysis. Blood, 2013, 122, 2145-2145.	1.4	0
99	Fucosylation Inhibitor, 2-Fluorofucose, Inhibits NF-ÎºB Activation and Vaso-Occlusion In Transgenic Sickle Mice. Blood, 2013, 122, 730-730.	1.4	0
100	Bloodâ€“Nanoparticle Interactions and in Vivo Biodistribution: Impact of Surface PEG and Ligand Properties. Molecular Pharmaceutics, 2012, 9, 2146-2155.	4.6	113
101	Complement, oxidants, and endothelial injury: how a bedside observation opened a door to vascular biology. Journal of Clinical Investigation, 2012, 122, 3044-3045.	8.2	11
102	MP4CO, a Pegylated Hemoglobin Saturated with Carbon Monoxide, Inhibits Microvascular Stasis in Transgenic Sickle Mice Through Heme Oxygenase-1.. Blood, 2012, 120, 2112-2112.	1.4	0
103	H-Ferritin Ferroxidase Activity Induces Cytoprotective Pathways and Inhibits Microvascular Stasis in Transgenic Sickle Mice. Blood, 2012, 120, 378-378.	1.4	0
104	Reduced-Intensity Conditioning Followed by Related Allografts in Hematologic Malignancies: Long-Term Outcomes Most Successful in Indolent and Aggressive Non-Hodgkin Lymphomas. Biology of Blood and Marrow Transplantation, 2011, 17, 1025-1032.	2.0	32
105	Erythroid-Specific Expression of Î²-globin from Sleeping Beauty-Transduced Human Hematopoietic Progenitor Cells. PLoS ONE, 2011, 6, e29110.	2.5	12
106	Selective Enhancement of Contractions to Î±1-adrenergic Receptor Activation in the Aorta of Mice With Sickle Cell Disease. Journal of Cardiovascular Pharmacology, 2011, 57, 263-266.	1.9	5
107	Protection of porcine endothelial cells against apoptosis with interleukinâ€4. Xenotransplantation, 2011, 18, 343-354.	2.8	8
108	Regulation of Heme Oxygenase-1 Protein Expression by miR-377 in Combination with miR-217. Journal of Biological Chemistry, 2011, 286, 3194-3202.	3.4	76

#	Article	IF	Citations
109	Plasma Hemoglobin and Heme Trigger Weibel Palade Body Exocytosis and Vaso-Occlusion in Transgenic Sickle Mice. Blood, 2011, 118, 896-896.	1.4	7
110	The Blood Monocyte - TNF - Endothelial Axis in Activation of Endothelial Tissue Factor in the Transgenic Sickle Mouse: Possible Relevance of Etanercept to Sickle Coagulopathy. Blood, 2011, 118, 1048-1048.	1.4	0
111	Carbon Monoxide Therapy Modulates Hematopoietic Stem Cell Development in Heme-Oxygenase-1 Knockout Mice. Blood, 2011, 118, 1318-1318.	1.4	0
112	Prevention of Venular Stasis, Circulatory Collapse and Mortality in Transgenic Sickle Mice Administered MP4CO, a Pegylated Hemoglobin Saturated with Carbon Monoxide. Blood, 2011, 118, 850-850.	1.4	0
113	The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice. Blood, 2010, 115, 2483-2490.	1.4	76
114	Heme oxygenase-1 gene delivery by Sleeping Beauty inhibits vascular stasis in a murine model of sickle cell disease. Journal of Molecular Medicine, 2010, 88, 665-675.	3.9	77
115	Red Cells, Hemoglobin, Heme, Iron, and Atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1347-1353.	2.4	200
116	Iron deficiency and diffuse nonscarring scalp alopecia in women: More pieces to the puzzle. Journal of the American Academy of Dermatology, 2010, 63, 1070-1076.	1.2	34
117	Pre-conditioning cryosurgery: Cellular and molecular mechanisms and dynamics of TNF-Î± enhanced cryotherapy in an in vivo prostate cancer model system. Cryobiology, 2010, 61, 280-288.	0.7	35
118	Heme Degradation and Vascular Injury. Antioxidants and Redox Signaling, 2010, 12, 233-248.	5.4	196
119	Heme and the Vasculature: How the Endothelium Protects Itself Against Toxic Iron. Blood, 2010, 116, SCI-25-SCI-25.	1.4	0
120	Exhaled Carbon Monoxide as a Marker of Hemolysis In Transgenic Mouse Models of Sickle Cell Anemia.. Blood, 2010, 116, 1642-1642.	1.4	0
121	ABO Mismatch Adversely Affects GvHD In Recipients of HLA Matched Unrelated Marrow or Peripheral Blood but Not Single or Double Umbilical Cord Blood Transplants. Blood, 2010, 116, 226-226.	1.4	2
122	Carbon Monoxide Therapy Reduces Reactive Oxygen Species Production and the Short-Term Hematopoietic Stem Cell Population In Heme-Oxygenase-1 Knockout Mice. Blood, 2010, 116, 4767-4767.	1.4	0
123	Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: Analysis of Graft Sources and Long-Term Outcome. Journal of Clinical Oncology, 2009, 27, 3634-3641.	1.6	92
124	Supression of hemin-mediated oxidation of low-density lipoprotein and subsequent endothelial reactions by hydrogen sulfide (H2S). Free Radical Biology and Medicine, 2009, 46, 616-623.	2.9	56
125	Historical perspective and clinical implications of the Pelgerâ€Huet cell. American Journal of Hematology, 2009, 84, 116-119.	4.1	47
126	Heme Oxygenase-1 Gene Therapy in a Murine Model of Sickle Cell Disease.. Blood, 2009, 114, 1527-1527.	1.4	0

#	Article	IF	Citations
127	The HDAC Inhibitors Trichostatin A (TSA) and Suberoylanilide Hydroxamic Acid (SAHA) Exhibit Multiple Modalities of Benefit for the Vascular Pathology of Sickle Disease.. Blood, 2009, 114, 2586-2586.	1.4	0
128	Tumor necrosis factor-Î±â€“induced accentuation in cryoinjury: mechanisms in vitro and in vivo. Molecular Cancer Therapeutics, 2008, 7, 2547-2555.	4.1	31
129	Potential Role of Heme Oxygenase-1 in Arsenic Trioxide and Hemin-Mediated Differentiation of Human Promyelocytic Leukemia Cells. Blood, 2008, 112, 3981-3981.	1.4	0
130	Gene-Specific Effects of the Histone Deacetylase Inhibitor TSA on Activation of a Pro-Inflammatory Endothelial Cell Phenotype by the Major Phagocyte Peroxidase-Derived Oxidant HOSCN.. Blood, 2008, 112, 1274-1274.	1.4	0
131	Carbon Monoxide Decreases Leukocytosis in Murine Sickle Cell Disease Models Via Decreased Granulopoiesis.. Blood, 2008, 112, 1433-1433.	1.4	0
132	Hypocalcemia during Autologous Stem Cell Transplant with Concurrent Biphosphonate Use in Patients with Multiple Myeloma. Blood, 2008, 112, 4335-4335.	1.4	0
133	Heme, Heme Oxygenase, and Ferritin: How the Vascular Endothelium Survives (and Dies) in an Iron-Rich Environment. Antioxidants and Redox Signaling, 2007, 9, 2119-2138.	5.4	174
134	Differentiation of Highly Conserved Host and Transgene mRNA in HO-1 Gene Therapy.. Blood, 2007, 110, 2266-2266.	1.4	0
135	Inhaled Carbon Monoxide: An Anti-Inflammatory Modulator in Transgenic Sickle Mice.. Blood, 2007, 110, 2268-2268.	1.4	2
136	The Major Phagocyte Peroxidase-Derived Oxidant, HOSCN (Hypothiocyanous Acid), Induces Proinflammatory and Cytoprotective Gene Expression in Endothelium: A Mechanism for Microlocalized Regulation of Inflammation.. Blood, 2007, 110, 3295-3295.	1.4	0
137	Factor V Leiden and hepatic artery thrombosis after liver transplantation. Clinical Transplantation, 2006, 20, 132-135.	1.6	17
138	Robust Vascular Protective Effect of Hydroxamic Acid Derivatives in a Sickle Mouse Model of Inflammation. Microcirculation, 2006, 13, 489-497.	1.8	19
139	Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. Journal of Clinical Investigation, 2006, 116, 808-816.	8.2	233
140	Sepsis Following Parenteral Sodium Ferric Gluconate Complex Infusion: A Report of Two Cases and Literature Review.. Blood, 2006, 108, 3729-3729.	1.4	0
141	Polynitroxyl albumin inhibits inflammation and vasoocclusion in transgenic sickle mice. Translational Research, 2005, 145, 204-211.	2.3	39
142	A â€˜touchâ€™ of the White platelet syndrome. Platelets, 2005, 16, 346-361.	2.3	5
143	Oxidative Stress and Vaso-Occlusion in Sickle Cell Disease: Role of Activated Leukocytes and Redox Active Iron.. Blood, 2005, 106, 3165-3165.	1.4	3
144	The White platelet syndrome: a new autosomal dominant platelet disorderI. Structural abnormalities. Platelets, 2004, 15, 173-184.	2.3	38

#	Article	IF	Citations
145	Microvascular blood flow and stasis in transgenic sickle mice: Utility of a dorsal skin fold chamber for intravital microscopy. American Journal of Hematology, 2004, 77, 117-125.	4.1	67
146	Heme Oxygenase-1: A Potential Modulator of Inflammation and Vaso-Occlusion in Sickle Cell Disease.. Blood, 2004, 104, 365-365.	1.4	1
147	Polynitroxyl Albumin Prevents Vaso-Occlusion in Transgenic Sickle Mice.. Blood, 2004, 104, 366-366.	1.4	1
148	Transgenic sickle mice have vascular inflammation. Blood, 2003, 101, 3953-3959.	1.4	195
149	PlGF: a link between inflammation and angiogenesis in sickle disease. Blood, 2003, 102, 1153-1153.	1.4	3
150	Pro-oxidant and cytotoxic effects of circulating heme. Blood, 2002, 100, 879-887.	1.4	549
151	Overview of infections and cardiovascular diseasesâ˜†â˜†â˜†. Journal of Allergy and Clinical Immunology, 2001, 108, S117-S120.	2.9	24
152	Cytomegalovirus inhibits p53 nuclear localization signal function. Journal of Molecular Medicine, 2001, 78, 642-647.	3.9	28
153	Heme protein-induced chronic renal inflammation: Suppressive effect of induced heme oxygenase-1. Kidney International, 2001, 59, 106-117.	5.2	194
154	Carbon Monoxide Generated by Heme Oxygenase-1 Suppresses the Rejection of Mouse-to-Rat Cardiac Transplants. Journal of Immunology, 2001, 166, 4185-4194.	0.8	440
155	Reperfusion injury pathophysiology in sickle transgenic mice. Blood, 2000, 96, 314-320.	1.4	198
156	Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood, 2000, 96, 2451-2459.	1.4	301
157	Infection and Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1417-1420.	2.4	181
158	Human cytomegalovirus immediate early proteins upregulate endothelial p53 function. FEBS Letters, 2000, 474, 213-216.	2.8	28
159	Reperfusion injury pathophysiology in sickle transgenic mice. Blood, 2000, 96, 314-320.	1.4	10
160	INTERCELLULAR ADHESION MOLECULE-1 EXPRESSION IN ENDOTHELIAL CELLS IS ACTIVATED BY CYTOMEGALOVIRUS IMMEDIATE EARLY PROTEINS1. Transplantation, 1999, 67, 137-144.	1.0	79
161	Heme and the Endothelium. Journal of Biological Chemistry, 1998, 273, 23388-23397.	3.4	71
162	A Microassay to Assess the Oxidative Resistance of Low-Density Lipoproteins. Clinical Chemistry, 1998, 44, 1762-1764.	3.2	27

#	Article	IF	Citations
163	Iron and Atherosclerosis: Inhibition by the Iron Chelator Deferiprone (L1). Journal of Surgical Research, 1997, 73, 35-40.	1.6	61
164	The endothelial biology of sickle cell disease. Translational Research, 1997, 129, 288-293.	2.3	94
165	Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. British Journal of Haematology, 1995, 91, 403-408.	2.5	236
166	Heme protein-mediated renal injury: A protective role for 21-aminosteroids in vitro and in vivo. Kidney International, 1995, 47, 592-602.	5.2	93
167	Potential role of viruses in thrombosis and atherosclerosis. Trends in Cardiovascular Medicine, 1995, 5, 128-133.	4.9	10
168	Analysis Of The Ul97 Phosphotransferase Coding Sequence In Clinical Cytomegalovirus Isolates And Identification Of Mutations Conferring Ganciclovir Resistance. Journal of Infectious Diseases, 1995, 171, 576-583.	4.0	243
169	Endothelial Activation and the Kidney: Vasomediator Modulation and Antioxidant Strategies. American Journal of Kidney Diseases, 1993, 21, 331-343.	1.9	31
170	Herpes Simplex Virus Decreases Endothelial Cell Plasminogen Activator Inhibitor. Thrombosis and Haemostasis, 1993, 69, 253-258.	3.4	22
171	Prothrombotic phenotype diversity of human aortic endothelial cells in culture. Thrombosis Research, 1992, 67, 135-145.	1.7	20
172	INHIBITION OF COMPLEMENT-MEDIATED ENDOTHELIAL CELL CYTOTOXICITY BY DECAY-ACCELERATING FACTOR. Transplantation, 1991, 52, 530-533.	1.0	246
173	Isolated relapse of acute myelogenous leukemia presenting as a gastric ulcer. American Journal of Hematology, 1991, 37, 270-273.	4.1	3
174	Evidence for a role of platelet activating factor in the pathogenesis of irreversible but not reversible myocardial injury after reperfusion in dogs. American Heart Journal, 1990, 120, 510-520.	2.7	38
175	Impermeant stilbene disulfonic acids block chemotactic peptide receptor function on human granulocytes. Inflammation, 1989, 13, 31-45.	3.8	4
176	Immunological Biocompatibility in Blood Substitutes. International Anesthesiology Clinics, 1985, 23, 47-62.	0.8	29
177	Bronchiolitis obliterans after bone marrow transplantation. American Journal of Hematology, 1985, 18, 325-328.	4.1	23
178	Ibuprofen inhibits granulocyte responses to inflammatory mediators. Inflammation, 1984, 8, 33-44.	3.8	69
179	Hemodynamic profile of adverse clinical reactions to Fluosol-DA 20%. Critical Care Medicine, 1984, 12, 428-431.	0.9	47
180	THERAPEUTIC RAMIFICATIONS OF THE INTERACTION OF COMPLEMENT, GRANULOCYTES, AND PLATELETS IN THE PRODUCTION OF ACUTE LUNG INJURY. Annals of the New York Academy of Sciences, 1982, 384, 489-495.	3.8	36